NO20044534L - Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer - Google Patents

Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer

Info

Publication number
NO20044534L
NO20044534L NO20044534A NO20044534A NO20044534L NO 20044534 L NO20044534 L NO 20044534L NO 20044534 A NO20044534 A NO 20044534A NO 20044534 A NO20044534 A NO 20044534A NO 20044534 L NO20044534 L NO 20044534L
Authority
NO
Norway
Prior art keywords
glucokinase activators
substituted phenylacetamides
substituted
phenylacetamides
formula
Prior art date
Application number
NO20044534A
Other languages
English (en)
Inventor
Wendy Lea Corbett
Nancy-Ellen Haynes
Robert Francis Kester
Paige Erin Mahaney
Ramakanth Sarabu
Joseph Samuel Grimsby
Jagdish Kumar Racha
Ka Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20044534L publication Critical patent/NO20044534L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48Y being a hydrogen or a carbon atom
    • C07C275/50Y being a hydrogen or an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Legemiddel Forbindelser med formel (I); hvori formel (U) representerer en substituert gmppe, en oksa-cykloalkylgruppe eller en tia-cykloalkylgmppe, er glukokinase-aktivatorer som er anvendelig ved behandling av type II diabetes.
NO20044534A 2002-04-26 2004-10-21 Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer NO20044534L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37616102P 2002-04-26 2002-04-26
PCT/EP2003/003844 WO2003095438A1 (en) 2002-04-26 2003-04-14 Substituted phenylacetamides and their use as glucokinase activators

Publications (1)

Publication Number Publication Date
NO20044534L true NO20044534L (no) 2004-12-22

Family

ID=29420328

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044534A NO20044534L (no) 2002-04-26 2004-10-21 Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer

Country Status (35)

Country Link
US (2) US7105671B2 (no)
EP (1) EP1501815B1 (no)
JP (1) JP4091600B2 (no)
KR (1) KR100669587B1 (no)
CN (1) CN1329386C (no)
AR (1) AR039665A1 (no)
AT (1) ATE346056T1 (no)
AU (1) AU2003232204B8 (no)
BR (1) BR0309546A (no)
CA (1) CA2482346C (no)
DE (1) DE60309856T2 (no)
DK (1) DK1501815T3 (no)
EA (1) EA011297B1 (no)
EC (1) ECSP045382A (no)
ES (1) ES2276097T3 (no)
GT (1) GT200300096A (no)
HK (1) HK1078088A1 (no)
HR (1) HRP20040953A2 (no)
IL (1) IL164780A (no)
MA (1) MA27113A1 (no)
MX (1) MXPA04010605A (no)
MY (1) MY135222A (no)
NO (1) NO20044534L (no)
NZ (1) NZ535706A (no)
PA (1) PA8572301A1 (no)
PE (1) PE20040451A1 (no)
PL (1) PL373701A1 (no)
PT (1) PT1501815E (no)
RS (1) RS93604A (no)
TN (1) TNSN04211A1 (no)
TW (1) TWI281917B (no)
UA (1) UA80427C2 (no)
UY (1) UY27787A1 (no)
WO (1) WO2003095438A1 (no)
ZA (1) ZA200407986B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04115996U (ja) * 1991-03-28 1992-10-15 東洋運搬機株式会社 ボートリフタ
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7812167B2 (en) 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CA2554310A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinase activating agents
EP1735322B1 (en) 2004-04-02 2011-09-14 Novartis AG Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes
EP1737870A1 (en) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
EP1740560A1 (en) * 2004-04-21 2007-01-10 Prosidion Limited Tri(cyclo) substituted amide compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
CN101035767A (zh) * 2004-08-12 2007-09-12 普洛希典有限公司 被取代的苯乙酰胺及其作为葡糖激酶激活剂的用途
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CA2613303C (en) * 2005-07-11 2012-06-19 Mitsubishi Tanabe Pharma Corporation An oxime derivative for use as a glucokinase activator
BRPI0615236A2 (pt) 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CN101296917A (zh) 2005-10-24 2008-10-29 霍夫曼-拉罗奇有限公司 由法沃斯基重排制备环状缩酮化酮及该方法在制备葡糖激酶活化剂70中的应用
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
WO2007115967A1 (en) * 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Crystalline isopropanol solvate of glucokinase activator
WO2007115968A2 (en) * 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
AR061644A1 (es) 2006-06-27 2008-09-10 Takeda Pharmaceutical Derivados de benzofurano
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CA2657566A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
TW200819457A (en) 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
US7902248B2 (en) * 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008080822A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Epimerization methodologies for recovering stereo isomers in high yield and purity
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
WO2008084872A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
JP5580201B2 (ja) * 2007-10-08 2014-08-27 アドビヌス・セラピューティクス・プライベート・リミテッド グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用
JP5287730B2 (ja) 2008-01-18 2013-09-11 アステラス製薬株式会社 フェニルアセトアミド誘導体
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CA2722733C (en) * 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
US20110021570A1 (en) 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
MX2019001481A (es) 2016-08-31 2019-05-15 Jiangsu Hengrui Medicine Co Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo.
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
US11076596B2 (en) 2017-09-18 2021-08-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE249241C (no) 1910-05-01 1912-07-13
US3431301A (en) 1966-03-24 1969-03-04 Hoffmann La Roche Process for producing methylhydrazine derivatives
US3776917A (en) 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
ES419319A1 (es) 1973-10-04 1976-03-01 Gallardo Antonio Sa Un procedimiento para la obtencion de derivados de acidos 3-benzoilfenilalcanoicos.
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5169951A (en) 1990-04-23 1992-12-08 Ciba-Geigy Corporation Process for preparing nematicidal compositions
DE69322118T2 (de) 1992-04-17 1999-05-20 Hodogaya Chemical Co Ltd Amino-Thiazolderivate und ihre Anwendung als Fungizide
US5556859A (en) 1994-12-22 1996-09-17 Dowelanco N-(4-pyrimidinyl)amide pesticides
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
ATE278680T1 (de) * 1999-03-29 2004-10-15 Hoffmann La Roche Glukokinase aktivatoren
BR0112658A (pt) * 2000-07-20 2003-06-24 Hoffmann La Roche Ativadores de benzeno-acetamida-glucoquinase substituìdos por alfa-acil e alfa heteroátomos

Also Published As

Publication number Publication date
TWI281917B (en) 2007-06-01
EA011297B1 (ru) 2009-02-27
JP2005535589A (ja) 2005-11-24
TNSN04211A1 (fr) 2007-03-12
US7259166B2 (en) 2007-08-21
CA2482346C (en) 2010-03-09
DE60309856D1 (de) 2007-01-04
ES2276097T3 (es) 2007-06-16
ZA200407986B (en) 2005-10-18
AU2003232204B2 (en) 2006-09-14
BR0309546A (pt) 2005-02-15
MY135222A (en) 2008-02-29
EP1501815B1 (en) 2006-11-22
PT1501815E (pt) 2007-01-31
UY27787A1 (es) 2003-10-31
WO2003095438A9 (en) 2004-12-23
AU2003232204A1 (en) 2003-11-11
US20030225283A1 (en) 2003-12-04
CN1329386C (zh) 2007-08-01
PL373701A1 (en) 2005-09-05
KR20040104633A (ko) 2004-12-10
MA27113A1 (fr) 2004-12-20
RS93604A (en) 2007-02-05
KR100669587B1 (ko) 2007-01-15
CA2482346A1 (en) 2003-11-20
WO2003095438A1 (en) 2003-11-20
DK1501815T3 (da) 2007-04-02
US7105671B2 (en) 2006-09-12
EP1501815A1 (en) 2005-02-02
HK1078088A1 (en) 2006-03-03
PE20040451A1 (es) 2004-07-21
UA80427C2 (en) 2007-09-25
DE60309856T2 (de) 2007-06-14
ECSP045382A (es) 2005-01-03
PA8572301A1 (es) 2004-05-26
ATE346056T1 (de) 2006-12-15
IL164780A (en) 2009-05-04
GT200300096A (es) 2004-01-15
TW200402418A (en) 2004-02-16
HRP20040953A2 (en) 2005-06-30
US20060178429A1 (en) 2006-08-10
IL164780A0 (en) 2005-12-18
NZ535706A (en) 2007-08-31
EA200401398A1 (ru) 2005-06-30
AR039665A1 (es) 2005-03-02
AU2003232204B8 (en) 2009-07-30
CN1649859A (zh) 2005-08-03
JP4091600B2 (ja) 2008-05-28
MXPA04010605A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
NO20052159L (no) Substituert (tiazol-2-yl)-amid eller sulfonamid som glykokinase-aktivatorer nyttige ved behandling av type 2 diabetes.
NO20034661L (no) Nociceptin-analoger
DK1474395T3 (da) Nicotinamidderivater, der er nyttige som p38-inhibitorer
NO20060688L (no) Fusjonerte aryl- og heteroarylderivater som modulatorer av metabolisme og profylakse og behandling av lidelser relatert til dette
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
CA2499329A1 (en) Indole-3-carboxamides as glucokinase (gk) activators
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
WO2004072031A3 (en) Phenylacetamides and their use as glucokinase modulators
NO20055977L (no) Nye benzimidazolderivater
NO20066055L (no) Pyridinderivater
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
NO20070570L (no) Forbindelser.
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
NO20054787D0 (no) Indenderivater som farmasotiske midler
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application